Giant cell arteritis is a systemic vasculitis and careful ... In a 2001 meta-analysis that included 941 biopsy proven cases of GCA, 4% of those with positive biopsies had "normal" ESRs.

Patients with giant cell arteritis have a greater risk for aortic complications than those with polymyalgia rheumatica.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Findings showed 46.4% of patients treated with upadacitinib 15mg achieved sustained remission compared with 29.0% of those who received placebo. The Food and Drug Administration (FDA) has approved ...

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA). The approval follows the recent marketing ...

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...

(RTTNews) - AbbVie (ABBV) Tuesday said the U.S. Food and Drug Administration (FDA) has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease ...

for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA)The approval is supported by ...

Giant cell arteritis (GCA) is the most common form of vasculitis in the older adult population. There are variable clinical presentations of this entity and no perfect diagnostic test, often ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.